ClinicalTrials.gg
CompletedNCT02743741Updated Sep 29, 2026

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

An interventional study of Lutetium-177 Octreotate in Neuroendocrine Tumors, sponsored by University Health Network, Toronto. Completed at 4 sites in Canada. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

How we know

Updated Sep 29, 2026Now CompletedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
195
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Neuroendocrine Tumors with a site in Canada — 11 open to participants now, 20 under way, 4 of them phase 3. Neuroendocrine Tumors · Canada.

Enrollment
14th of 33
195 · median 160
Started
2016
with 3 others
No phase
3 of 42
none open now
Registered
16th of 42
by date
Lead sponsor
5 of 42
University Health Network, Toronto

Among the 42 studies in Neuroendocrine Tumors with a site in Canada, this one is the 14th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2016, is one of 3 with no phase, and was the 16th registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

11 of the 42 studies in Neuroendocrine Tumors with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Neuroendocrine Tumors with a site in Canada, or all of them as a file.
02

Study summary

This is a prospective single arm, multicenter study will evaluate the efficacy and safety of Lutetium-177 Octreotate in patients with neuroendocrine tumors who has positive Somatostatin receptor identified by 68Ga-DOTATATE. 195 patients will be enrolled totally. Patient who has progressed with neuroendocrine tumor will be evaluated by the tumor board first and eligible patients will undergo diagnostic Ga 68 PET scan. Patients who showed Somatostatin will undergo 4 cycles of Lu-DOTATATE treatment. Dose adjustment for Cycle 2-4 will be made based on individualized dosimetry, as well as creatinine clearance and hematological parameters. Patients will be evaluated progression free survival at 12 months from last dose. Patients who are negative for somatostatin will not receive 68Ga-DOTATATE treatment but will be followed until progression and acts as control group.

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

Keywords

  • Somatostatin Receptor Positive Neuroendocrine Tumors
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Please note that only Ontario residents will be eligible for participation in this trial.

Inclusion criteria

Inclusion Criteria:

  1. -proven neuroendocrine tumor
  2. performance status ≤ 2
  3. Ki-67 index ≤ 30%
  4. Evidence of progressive disease demonstrated by imaging within six months prior to study enrollment as defined by v1.1.

    • Tumor board discussion of cases to confirm suitability for participation in the clinical trial is required. Review should include but not limited to imaging review, pathology (including Ki 67) and treatment options.
    • Patients with objective evidence (imaging, or biochemical) that is insufficient to be classified by RECIST 1.1 criteria can be eligible if after provincial multidisciplinary tumor board discussion a consensus for progression eligibility is reached.
    • The tumor board would consider exemptions if the magnitude of change is adequate by other definitions (e.g. using structural and contrast patterns and biochemical changes).
    • Where clinically indicated, formal consultation on pathology, diagnostic imaging to facilitate criteria assessment (including 68Ga PET performed as part of the diagnostic procedure) is strongly recommended.
  5. Adequate lab parameters within 2 weeks prior to enrollment:

    • Serum creatinine ≤ 150 μmol/L
    • Calculated or measured ≥ 30 mL/min (measured GFR may be done within 4 weeks prior to enrollment)
    • ≥ 90 g/L
    • WBC ≥ 2 x 109/L
    • ≥ 100 x 109/L
  6. Adequate liver function tests within 2 weeks prior to enrollment:

    • total ≤ 5 x
    • ≤ 5 x ULN
    • AST ≤ 5 x ULN
    • alkaline phosphatase ≤ 5 x ULN
  7. Signed
  8. Patients with extensive bone (e.g. >25% of bone marrow involvement are eligible but requires careful monitoring of hematological reserve
  9. Subject's willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
  10. Age ≥ 18 years.

Exclusion criteria

Exclusion Criteria:

  1. \<12 weeks
  2. An option for curative surgical or medical therapy or local liver embolization is feasible
  3. Candidate for curative and/or debulking surgical resections
  4. Systemic, biologic, other radioisotope, embolization therapies within ≤4 weeks prior to the first dose of 177Lu.
  5. Prior radiotherapy to target lesion(s) within ≤12 weeks prior to study enrollment [radiotherapy to non-target lesions permitted].
  6. Prior therapy with any systemic radionuclide therapy.
  7. Radiotherapy to more than 25% of the bone marrow.
  8. Known (unless have been treated and are stable for ≥ 6 months).
  9. Uncontrolled diabetes mellitus
  10. Co-morbidities that may interfere with delivery of 177Lu (e.g. urinary incontinence).
  11. Second cancer(s) with clinical or biochemical progression within the last 3 years.
  12. Pregnancy or breast feeding. Female subjects must be surgically sterile or , or must agree to use effective during the period of therapy. All female subjects with must have a negative pregnancy test (serum) prior to enrolment. Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate
  13. Other condition, illness, psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation, 68Ga or 177Lu administration, or may interfere with the interpretation of study results and in the judgment of the investigator would make the patient inappropriate for entry into this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
195 participants (actual)

Study arms

  • Experimental
    Lutetium-177 Octreotate

    Lutetium-177 Octreotate 200 mCi (7.4 GBq) by IV for 18-30 weeks

    Drug: Lutetium-177 Octreotate

Interventions

  • DrugLutetium-177 Octreotate

    Radiopharmaceutical

    Also known as: Lu-DOTATATE, [Lu-177]-DOTATATE

06

What researchers measure

Primary outcomes

  1. The proportion of patients progression-free using RECIST 1.1 criteria

    Time frame: Up to 12 months

Secondary outcomes

  1. The overall response rate as determined by structural imaging using RECIST criteria.

    Time frame: Up to 5 years

  2. The biochemical response rate (as defined by biochemical responses: serum chromogranin A and 24 hr urinary 5HIAA).

    Time frame: Up to 5 years

  3. The acute and late adverse effects of Lu-DOTATATE (177Lu) using CTCAE Version 4.03

    Time frame: Up to 5 years

  4. Overall survival

    Time frame: Up to 5 years

  5. The Quality of Life (QoL) in patients treated with Lu-DOTATATE (177Lu)

    Time frame: Up to 5 years

07

Study locations

4 sites
  • Juravinski Cancer Centre
    Hamilton, Ontario, Canada
  • London Health Sciences Centre
    London, Ontario, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario, Canada
  • Sunnybrook Odette Cancer Center
    Toronto, Ontario, Canada
08

References and documents

Publications

  • Macsuka MJ, Driscoll B, Yeung IWT, Publicover J, Metser U, Juergens R, Myrehaug SD, Laidley D, Wong RK, McGowan DR, Vallis KA. Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response to 177Lu-DOTATATE in Neuroendocrine Tumors. J Nucl Med. 2026 May 1;67(5):751-757. doi: 10.2967/jnumed.125.271039. PubMed 41611479 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Aug 2026, 121 months.

Of 35 interventional studies with no phase under Neuroendocrine Tumors, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 102. This study's 121 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Jun 2026 → Aug 2026 and completion Jun 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2016
First posted
Apr 19, 2016
StartActual
Jul 15, 2016
Primary completionActual
Aug 18, 2026was Jun 2026
CompletionActual
Aug 18, 2026was Jun 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 29, 2026
Primary completion
Jun 2026→Aug 18, 2026 (actual)
Sep 29, 2026
Study completion
Jun 2026→Aug 18, 2026 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Active, not recruiting→Completed
    Primary completion Jun 2026→Aug 18, 2026 (now actual)
    Study completion Jun 2026→Aug 18, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02743741
Collaborators
Ozmosis Research Inc., Cancer Care Ontario, Canadian Molecular Imaging Probe Consortium
Responsible party
Sponsor
First posted
Apr 19, 2016
Start date
Jul 15, 2016
Primary completion
Aug 18, 2026
Completion
Aug 18, 2026
Last update
Sep 29, 2026

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion